Factors associated with first- and second-line attrition among metastatic breast cancer patients

被引：0
|
作者：
Blondeaux, Eva
Boni, Luca
Chila, Giovanna
Dri, Arianna
Caputo, Roberta
Poggio, Francesca
Fabi, Alessandra
Arpino, Grazia
Pravisano, Federico
Geuna, Elena
Ruelle, Tommaso
Giannubilo, Irene
de Laurentiis, Michelino
Puglisi, Fabio
Bighin, Claudia
Lambertini, Matteo
Montemurro, Filippo
Del Mastro, Lucia
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-06-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-06-01
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world
    Blondeaux, E.
    Boni, L.
    Chila, G.
    Dri, A.
    Caputo, R.
    Poggio, F.
    Fabi, A.
    Arpino, G.
    Pravisano, F.
    Geuna, E.
    Delucchi, V.
    Ruelle, T.
    Giannubilo, I.
    De Laurentiis, M.
    Puglisi, F.
    Bighin, C.
    Lambertini, M.
    Montemurro, F.
    Del Mastro, L.
    ESMO OPEN, 2025, 10 (02)
  • [2] First- and second-line therapy of metastatic colorectal cancer
    Terstriep, Shelby
    Grothey, Axel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (06) : 921 - 930
  • [3] Metastatic colorectal cancer:: First- and second-line treatment in 2005
    Rougier, P
    Lepère, C
    SEMINARS IN ONCOLOGY, 2005, 32 (06) : S15 - S20
  • [4] Efficacy and safety of oral vinorelbine (NVBO) in first- or second-line metastatic breast cancer (MBC)
    Blancas, I.
    Morales, S.
    Diaz, N.
    Barnadas, A.
    Gonzalvez, M. L.
    del Barco, S.
    Lopez de Ceballos, M. H.
    Perez, F. J.
    Llombart-Cussac, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Endocrine therapies for patients with recurrent breast cancer: Predictive factors for responses to first- and second-line endocrine therapies
    Kurebayashi, J
    Sonoo, H
    Inaji, H
    Nishimura, R
    Iino, Y
    Toi, M
    Kobayashi, S
    Saeki, T
    ONCOLOGY, 2000, 59 : 31 - 37
  • [6] Docetaxel: Efficacy in first- and second-line therapy of advanced breast cancer
    Crown, J
    ONKOLOGIE, 2000, 23 : 1 - 3
  • [7] Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer
    Lee S. Schwartzberg
    Patrick Cobb
    Mark S. Walker
    Edward J. Stepanski
    Arthur C. Houts
    Supportive Care in Cancer, 2009, 17
  • [8] Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer
    Schwartzberg, Lee S.
    Cobb, Patrick
    Walker, Mark S.
    Stepanski, Edward J.
    Houts, Arthur C.
    SUPPORTIVE CARE IN CANCER, 2009, 17 (08) : 1081 - 1088
  • [9] Combination treatment with aromatase inhibitor and capecitabine as first- or second-line treatment in metastatic breast cancer.
    Alvarado Miranda, Alberto
    Limon, Jesus
    Lara Medina, Fernando
    Arce, Claudia
    Wolfgang Zinser, Juan
    Bargallo Rocha, Enrique
    Mayte Villarreal-Garza, Cynthia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Prognostic Factors for Complete Debulking in First- and Second-Line Ovarian Cancer
    Harter, Philipp
    Hilpert, Felix
    Mahner, Sven
    Kommoss, Stefan
    Heitz, Florian
    Pfisterer, Jacobus
    du Bois, Andreas
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 : S14 - S17
12345